Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 2, Canaccord Genuity cut its price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) from $140 to $99 but kept its Buy rating on the stock. This adjustment comes after the company reported that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism ...